Berlin’s Charité is probably one of the best known and most renowned hospitals in Germany. Highly respected doctors and medical specialists work here. But the Charité is also an “incubator” for interesting medical spin-offs, including the medtech company Aignostics. The Boehringer Ingelheim Venture Fund is now participating in Aignostics alongside other investors. This article is based on the unique List of the 200 most important venture capital investors in Germany.
- Article based on the database of the 200 most important Venture Capital Fonds in Germany
- Useful information such as investment focus, selection of top investments, year of foundation, etc.
- Including contact data: E-mail address, address, URL, telephone number, management, etc.
- Direct download as Excel file via the online store possible
- Free preview file available on request
- Database is perfectly suited for identifying venture capital funds
Five million euros for innovative medical diagnostics
The Aignostics story began in 2018 with the inclusion of researchers from the Charité and TU Berlin in the Digital Health Accelerator Program of the Berline Institute of Health, a scientific institution of the State of Berlin. Within two years, this has developed into a dynamic start-up, in which an interdisciplinary team of physicians, IT experts and business people work together. Aignostics develops intelligent solutions for drug research, clinical diagnostics and medical research. With the help of machine learning and artificial intelligence, analyses and evaluations will in future be more efficient, faster and more accurate.
The Boehringer Ingelheim Venture Fund is the venture capital fund of Boehringer Ingelheim, the largest research-based pharmaceutical company in Germany. The fund has been in existence since 2010 and invests primarily in business models for new therapies and in the digital health sector. The Aignostics commitment fits in seamlessly with this. Together with other investors, the Boehringer Ingelheim Venture Fund provides Aignostics with a total of five million euros to finance longer-term projects. Co-investors are High-Tech Gründerfonds and IBB Beteiligungsgesellschaft der Förderbank des Landes Berlin IBB.
Picture source: National Cancer Institute via Unsplash
You also might like our B2B customer acquisition whitepaper about sales in Germany.